Cryo‑Cell International, Inc. reported fiscal first‑quarter 2026 revenue of $7.68 million, up 3.8% from $7.37 million in the same period last year. The increase was driven almost entirely by the private cord blood banking segment, which generated $7.64 million in processing and storage fee revenue, a slight decline from $7.87 million in Q1 2025. Public‑banking revenue collapsed to $1,400, down 98% from $82,000 in the prior year, reflecting a sharp loss of public‑banking contracts.
The company’s earnings per share of $0.01 beat the consensus estimate of –$0.09 by $0.10, a 111% upside that underscores the company’s ability to control costs amid a revenue decline. Revenue beat expectations of $7.6 million, a $0.08 million lift that was largely attributable to the private‑banking segment’s resilience. Net income, however, fell to $47,000 (approximately $0.01 per share) from $283,000 (about $0.03 per share) in Q1 2025, a 83% year‑over‑year decline that highlights the impact of the public‑banking revenue collapse and the company’s ongoing litigation costs.
Management did not provide new guidance for the remainder of the fiscal year, but it reiterated that the dividend policy remains unchanged. The company continues to face a material legal risk from its litigation with Duke University over a terminated licensing agreement, a dispute that could affect future growth prospects and cash‑flow generation. The earnings beat, coupled with the sharp net‑income decline and the public‑banking revenue collapse, signals a mixed outlook: strong cost discipline in the core private‑banking business but significant headwinds from the public‑banking segment and legal expenses.
The results suggest that while Cryo‑Cell’s core private‑banking operations remain profitable, the company’s overall profitability is under pressure from declining public‑banking revenue and litigation costs. Investors will likely monitor the company’s ability to sustain dividend payments and manage legal risks while seeking to understand whether the private‑banking segment can offset the losses in the public‑banking business in future quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.